ENDO 2019

New Orleans, LA US

Click the start button to:

  1. Choose the desired credits and/or certificate to be awarded
  2. Complete a brief meeting evaluation
  3. Enter the credit total commensurate with ENDO 2019 accredited session attendance
  4. View/Download/Print Certificate

In compliance with Accreditation Council for Continuing Medical Education policy and procedures, the Endocrine Society will be unable to accept MOC credit submissions after December 31, 2019.  Please plan to claim your credits accordingly.

To calculate your credits:

Use the quick credit guide below or track your session attendance via the Daily Schedule (click here for instructions), Program Planner, or the ENDO 2019 App.

The maximum number of credits per day:


Sat 3/23

Sun 3/24

Mon 3/25

Tue 3/26 


Maximum Credits






Quick guide by session type

Session Type

Typical Credits per Session Type

Symposium (S)
Oral Abstracts (OR)


Plenary (PL)
Clinical Practice Guideline (CPG)
Master Clinician (MC)

Knockout Rounds (KO)
Career Development Workshops (CDW)



Meet-The-Professor (M)
Meet-The-Program-Director (MPD)
Clark T. Sawin History of Endocrinology Lecture  (CTS)
Endocrine "Year In" (YI)



Select other sessions, as indicated


* CME values may vary, please refer to the session credit information in the ENDO 2019 app to determine the amount of CME credit offered for each session.

Need your transcript?

Use the Add to Schedule function in the ENDO 2019 app, which allows you to identify the sessions attended and receive a meeting transcript via email. You are responsible for creating your own transcript by adding the sessions attended to your Schedule/Agenda through the app. Once compiled, click the My Schedule tile on the app home screen and click Export My Shortlist.  Schedule creation can be completed at any time so it is also a good planning resource.

Learning Objectives

Sessions at ENDO cover a full spectrum of research and clinical topics in endocrinology, including diabetes, obesity, lipid disorders, reproduction and infertility, osteoporosis, thyroid disease, growth hormone disorders, pituitary tumors, adrenal insufficiency, and topics therein. Upon completion of this educational activity, attendees will be able to (or better able to):

  • Demonstrate updated knowledge of the pathophysiology, diagnosis, and treatment of diabetes, obesity, cardiovascular disease, dyslipidemia, as well as adrenal, metabolic, bone, pediatric, pituitary, thyroid, and reproductive endocrine disorders
  • Discuss state-of-the-art research in endocrinology
  • Practice updated clinical skills for more effective diagnosis, management, and treatment of endocrine disorders and related sequelae
  • Apply updated knowledge and clinical skills in improving patient care
  • Construct new research questions based on updated scientific and clinical advances in endocrinology-related disciplines

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Medical Knowledge
Topic Area: 
Adrenal/HPA Axis
Bone and Calciotropic Hormones
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Endocrine Disruptors
Quality Improvement and Healthcare Delivery
General Endocrinology
Intercellular Signaling and Gene Regulation
Hormone Abuse
Growth Disorders
Health Disparities
Hormones and Cancer
Men’s Health
Neuroendocrinology and Pituitary
Nuclear Receptors and Steroid Hormones
Pediatric Endocrinology
Thyroid/HPT Axis
Women’s Health
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Activity summary
Course opens: 
Course expires: 
Ernest N. Morial Convention Center
900 Convention Center Blvd.
New Orleans, LA 70130
United States

For more travel, hotel, and additional destination-specific information visit the ENDO 2019 Travel Page here


As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Annual Meeting Steering Committee.


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

To view disclosure information for all ENDO presenters, please view the full schedule. Within each session abstract and session description, speaker disclosure is presented.


Susan J. Mandel, MD, MPH, Endocrine Society President
Perelman School of Medicine, University of Pennsylvania

E. Dale Abel, MBBS, MD, PhD, Endocrine Society President-Elect
University of Iowa

Gregory A. Brent, MD, ENDO 2019 Chair
VA Greater LA Healthcare

W. Lee Kraus, PhD, Basic Science Chair
University of Texas Southwestern Medical Center

Ghada El-Hajj Fuleihan, MD, MPH, Clinical Science Chair
American University of Beirut

Susan A. Sherman, MD, Physician-In-Practice Chair
Aurora Medical Associates, PC

Annual Meeting Steering Committee
Cynthia L. Andoniadou, PhD; Sherri-Ann Burnett-Bowie, MD, MPH; Eliot Brinton, MD; Francesco S. Celi, MD; Mark S. Cooper, MD,PHD, FRCP, FRACP; Ann Danoff, MD; Dawn B. Davis, MD,PhD; Scott M. Dehm, PhD; Marie B. Demay, MD; Matthew T. Drake, MD, PhD; Maralyn R. Druce, MD, PhD; Robert Eckel, MD; Ismaa S. Farooqi, PhD, FRCP, FMedSci; Richard A. Feelders, MD,PhD; Lauren M. Fishbein, MD, PhD; Larry A. Fox, MD; Rana K. Gupta, PhD; Aylin C. Hanyaloglu, PhD; Megan R. Haymart, MD; Terence Hebert, Bsc, Msc, PhD; Anders Juul, MD,PhD,DMSC; Bassil Kublaoui, MD; Peter Kopp, MD; Bruce Murphy, PhD, FCAHS; Nicola Napoli, MD, PhD; Kendall W. Nettles, PhD; Nicola C. Partridge, PhD; Margareta D. Pisarska, MD; Sally Radovick, MD; William E. Rainey, II, PhD; Inez Rogatsky, PhD; Darleen Sandoval, PhD; Rebecca E. Schweppe, PhD; Stephanie B. Seminara, MD; Jennifer A. Sipos, MD; Ron T. Varghese, MBBS; Adrian V. Vella, MD, FRCP; Selma F. Witchel, MD; Morag J. Young, PhD

The following AMSC peer reviewers reported relevant financial relationship(s): E. Dale Abel, MBBS, MD, PhD, Advisory Board Member, Novo Nordisk. Eliot Brinton, MD, Advisor and Speaker: Akcea, Amarin, Amgen, Kowa, Merck, Regeneron, Sanofi-Aventis and an Advisor, Balchem, PTS Diagnostics; Speaker, Boehringer-Ingelheim, Novo Nordisk. Francesco S. Celi, MD, MHSc, Advisory Board Member, LioTriDev, IBSA. Dawn B. Davis, MD, PhD, Site PI for clinical trial, Eiger Pharmaceuticals. Scott M. Dehm, PhD, Consultant, Janssen Research and Development LLC, Celgene. Marie B. Demay, MD, (Spouse) CMO - Syros Pharmaceuticals. Maralyn R. Druce, MD, PhD, Advisory Board Member – Specific Consultations, Ipsen. Robert Eckel, MD, Scientific Consultant for Sanofi Aventis, Regeneron Pharmaceuticals and a scientific Advisor for Novo Nordisk, Merck, Amgen. Richard A. Feelders, MD, PhD, Research Grant Recipient, Novartis, Ipsen. Anders Juul, MD, PhD, DMSC, Speakers Bureau, Novo Nordisk, Pfizer, Ferring, Merck, Bayer, Sponsor and PI of a clinical multicenter trial (NESGAS), Department research grant, Ferring, Department funding to participate in the clinical trial (PORIYA), Co-investigator in a Ferring-sponsored clinical trial, Department grantee, Diurnal, and Principal investigator for participation in a multicenter study (RCT) on long-acting hydrocortisone (Chronocort) in CAH. W. Lee Kraus, PhD, Founder, consultant, and stock holder for Ribon Therapeutics, Inc. - a start-up pharma company working in the PARP space.Nicola Napoli, MD, PhD, European Advisory Board Member, UCB, Eli Lilly, Consultant, Amgen, Lilly. Sally Radovick, MD, Consultant regarding GH Treatment, CVS Caremark; retail pharmacy and health care company. William E. Rainey, II, PhD, Scientific Advisory Board Member, Millendo Therapeutics. Darleen Sandoval, PhD, Research Funding, Novo Nordisk, Ethicon, Zafgen Speaker, Novo Nordisk. Stephanie B. Seminara, MD, Scientific Advisory Board Member, Astellas. Jennifer A. Sipos, MD, Advisory Board Consultant and Speaker, Genzyme. Ron T. Varghese, MBBS, Shareholder, Celgene, Mannkind Corp, Merck. Adrian V. Vella, MD, FRCP, Principal Investigator, Novo Nordisk, Investigator, XOMA (multi-center study), Member of Advisory Board, VTV Therapeutics, Bristol Myers Squibb.

The following AMSC peer reviewers reported no relevant financial relationships: Cynthia L. Andoniadou, PhD; Sherri-Ann Burnett-Bowie, MD, MPH; Gregory A. Brent, MD; Mark S. Cooper, MD, PhD; Ann Danoff, MD; Matthew T. Drake, MD, PhD; Ismaa S. Farooqi, PhD, FRCP, FMedSci; Ghada El-Hajj Fuleihan, MD, MPH; Lauren M. Fishbein, MD, PhD; Larry A. Fox, MD; Rana K. Gupta, PhD; Aylin C. Hanyaloglu, PhD; Megan R. Haymart, MD; Terence Hebert, Bsc, Msc, PhD; Peter Kopp, MD; Bassil Kublaoui, MD, PhD; Susan J. Mandel, MD, MPH; Bruce Murphy, PhD, FCAHS; Kendall W. Nettles, PhD; Nicola C. Partridge, PhD; Margareta D. Pisarska, MD; Inez Rogatsky, PhD; Rebecca E. Schweppe, PhD; Susan A. Sherman, MD; Selma F. Witchel, MD; Morag J. Young, PhD.

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.


The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.


The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.


When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information be disclosed to the learners. Uses of some pharmaceutical agents, medical devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the United States Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” uses be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before prescribing or recommending any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


The Endocrine Society is proud to partner with industry to advance excellence and promote scientific discovery, medical practice and human health.: 

AbbVie Inc.; Amarin Pharma Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai Inc.; Ethicon Endo-Surgery, Inc.; Ferring Pharmaceuticals Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc., Pfizer, Inc.; Radius Health, Inc.; Strongbridge Biopharma; The Leona M. and Harry B. Helmsley Charitable Trust

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.The Endocrine Society designates this live activity for a maximum of 29.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Accreditation Council for Continuing Medical Education (EACCME) and the American Medical Association (AMA) signed an agreement of mutual recognition of CME credits between Europe and the USA whereby:

  • European physicians attending an event in the USA had their credits recognized in Europe and American physicians attending an event in Europe had their credits recognized in the USA.

The Endocrine Society designates this educational activity for a maximum of 29.5 AMA PRA Category 1 Credit(s)™ for ENDO 2019. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. These credits can be converted by the EACCME into European CME credits and/or into National credits by the European National Authorities.

Maintenance of Certification (MOC):

American Board of Internal Medicine (ABIM)Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to a maximum of 29.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 20 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM) or American Board of Pediatrics (ABP), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers:

    Your ABP Number: [current-user:profile-profile:field-number-abp]*

    Your ABIM Number: [current-user:profile-profile:field-number-abim]*

    *If your ABP or ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.

  2. Update Profile


The following Endocrine Society ENDO 2019 presentations have been approved for ECNU Recertification Credit for a maximum of 14 CME credit hours.




CME Hours

Monday, March  25, 2019

8:00  AM - 8:45 AM

Short- and Long-Term Effects of RAI in Adults and Children


Monday, March  25, 2019

2:00  PM - 2:45 PM

Thyroid Cancer: When Is Lobectomy Not Enough?


Monday, March  25, 2019

11:00  AM - 12:30 PM

From Thyroid Nodules to Thyroid Cancer: Diagnosis and Treatment


Monday, March  25, 2019

9:15  AM - 10:45 AM

Advanced Thyroid Cancers: New Insights and Treatments


Saturday, March  23, 2019

2:00  PM - 2:45 PM

Thyroid Hormone Preparations: If, When, and Why You Should Deviate from Levothyroxine


Saturday, March  23, 2019

4:15  PM - 5:45 PM

A Lumpy Ordeal: The Evolving Management of Thyroid Nodules


Sunday, March 24,  2019

9:15  AM - 10:15 AM

Year in Thyroid Healthcare Delivery


Sunday, March 24,  2019

8:00  AM - 8:45 AM

Molecular Markers  Guiding Intervention and Treatment


Sunday, March 24,  2019

8:00  AM - 8:45 AM

Pediatric Thyroid Cancer Guidelines: Case Examples and Critical Points


Sunday, March 24,  2019

1:45  PM - 2:30 PM

Endo Emergencies: Thyroid Storm and Myxedema Coma


Sunday, March 24,  2019

11:00  AM - 12:30 PM

The Impact of Genetics, Age, and Medications on

Thyroid Diseases and Treatment


Sunday, March 24,  2019

4:00  PM - 5:30 PM

The Impact of the Thyroid on Fertility, Pregnancy, and

the Neonate


Tuesday, March  26, 2019

11:45  AM - 12:45 PM

Endocrine Debate: Thyroid Diseasein Pregnancy: To Screen, or Not to Screen?


Tuesday, March  26, 2019

9:45  AM - 10:30 AM

Interactive Interpretation of Thyroid Ultrasound


Click "Start" to:

  • Provide ENDO2019 Feedback
  • Obtain Certificate of Attendance and/or Participation
  • Claim up to 29.50 ABIM MOC points
  • Claim up to 20 ABP MOC Part 2 points
  • Claim up to 29.50 CME credits